Janssen Pharmaceutica Nv

Chiesi Farmaceutici S.p.a.

Galapagos Nv

Burritt, Andrew

Wolfgang Schmidt

Martin James Inglis Andrews

Mark Stuart Chambers

Kim Louise Hirst

Juha Andrew Clase

Ian Linney

Fabio Rancati

Chris Knight

Paul John Edwards

Angus MacLeod

Gregory Bar

Andrea Rizzi

Laura Carzaniga

Grégory Louis Joseph Bar

Veronique Birault

Philip Huxley

Clifford John Harris

Reginald Christophe Xavier Brys

Giovanni Alessandro Tricarico

Olga Raquel Pinto Santos Oliveira Roussel

Sébastien Laurent Xavier Martina

Xueliang Tao

Michael Barnes

Friedrich Erich Karl Kroll

Andrew Burritt

Paul Edwards

Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.

Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R, R, Rand Ras defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.

Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases

Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following:  The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Novel imidazo[-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Growing community of inventors

Saffron Walden, United Kingdom

Wolfgang Schmidt